| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
ZINC-12409120 targets ERK, a key component of the mitogen-activated protein kinase (MAPK) pathway. ERK is involved in cell proliferation, differentiation, and survival. The compound exerts its inhibitory effect by a unique mechanism: it interferes with the FGF23:α-Klotho interaction, which leads to the inhibition of ERK activity. This is a distinct mechanism from direct ATP-competitive kinase inhibition.
|
|---|---|
| ln Vitro |
Through a ternary complex made up of FGF23, FGFR, and α-Klotho, FGF23 can cause hypophosphatemia [1]. With an IC50 of 5 μM, ZINC12409120 (1 nM-0.1 mM; 5 h) suppresses the ERK reporter activity induced by FGF23 (1 μM) [1]. ZINC12409120 (10 μM; 5 h) shows no inhibitory effect on EGFR tyrosine kinase or EGF/EGFR interaction, but it particularly inhibits FGF23:α-Klotho-mediated ERK activity, but not EGF-mediated ERK activation [1]. As per pkCSM64 (http://biosig.unimelb.edu.au/pkcsm/), ZINC12409120 has a half-life of 8.4 hours [1].
In vitro, ZINC-12409120 is a selective ERK inhibitor with an IC50 of 5.0 μM. It inhibits ERK activity by disrupting the FGF23:α-Klotho interaction. Specific cellular assay data, such as effects on ERK phosphorylation or cell proliferation, are not detailed in the available sources. |
| ln Vivo |
Specific in vivo activity data for ZINC-12409120 are not provided in the available sources. As a selective ERK inhibitor, it would be expected to have effects in models of cancer or other diseases where the MAPK pathway is dysregulated. However, no specific studies are described.
|
| Enzyme Assay |
A cell-free assay for ZINC-12409120 is not a conventional kinase inhibition assay because its mechanism involves disrupting a protein-protein interaction. Its activity is measured by assessing its ability to inhibit ERK activity in cells. The IC50 of 5.0 μM is determined in cell-based assays.
|
| Cell Assay |
Cell proliferation assay[1]
Cell Types: Human embryonic kidney (HEK) 293T cell Tested Concentrations: 1 nM-0.1 mM Incubation Duration: 5 hrs (hours) Experimental Results: Inhibits FGF23-mediated ERK reporter gene activity in a dose-dependent manner with an IC50 of 5 μM . FGF23-mediated ERK activity was also diminished by 70%. Cellular assays for ZINC-12409120 would typically involve measuring its effects on ERK phosphorylation and downstream signaling. Cells are treated with the compound, and the phosphorylation of ERK and its substrates is measured by Western blotting. The compound's ability to inhibit cell proliferation can also be assessed. |
| Animal Protocol |
In vivo animal experiments for ZINC-12409120 are not described in the available sources. As a research compound, it could be evaluated in animal models of cancer or other diseases. However, no specific protocols or data are provided.
|
| ADME/Pharmacokinetics |
ZINC-12409120 has a molecular formula of C20H16N4O2 and a molecular weight of 344.37 g/mol. It is a solid. Specific pharmacokinetic parameters are not provided in the available sources. As a research compound, it is intended for preclinical studies.
|
| Toxicity/Toxicokinetics |
Toxicity data for ZINC-12409120 are not provided in the available sources. As a research compound, it is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
ZINC-12409120 (CAS: 1010888-06-8) is a selective ERK inhibitor with an IC50 of 5.0 μM. It is also known as R-4584. The compound inhibits ERK activity by disrupting the FGF23:α-Klotho interaction. It is used in research to study the MAPK/ERK signaling pathway. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
C20H16N4O2
|
|---|---|
| Molecular Weight |
344.37
|
| Exact Mass |
344.127
|
| CAS # |
1010888-06-8
|
| PubChem CID |
42581967
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
530
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(CC2=CC=CC=C21)C(=O)C3=NC(=NO3)C4=C5C=CNC5=CC=C4
|
| InChi Key |
BIUXGRRZAUBPEA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16N4O2/c25-20(24-11-9-13-4-1-2-5-14(13)12-24)19-22-18(23-26-19)16-6-3-7-17-15(16)8-10-21-17/h1-8,10,21H,9,11-12H2
|
| Chemical Name |
3,4-dihydro-1H-isoquinolin-2-yl-[3-(1H-indol-4-yl)-1,2,4-oxadiazol-5-yl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9039 mL | 14.5193 mL | 29.0385 mL | |
| 5 mM | 0.5808 mL | 2.9039 mL | 5.8077 mL | |
| 10 mM | 0.2904 mL | 1.4519 mL | 2.9039 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
